Clinical trials: Non Alcoholic Fatty Liver
Non-Alcoholic Fatty Liver Disease, Probiotics MeSH Descriptor Data 2018
Effects of Probiotic on Inflammation and Microbiota in Patients With NASH
Individuals with clinically identified non-alcoholic fatty liver disease will undergo baseline evaluation of IL-17 and other inflammatory markers as well as microbiome determination.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Probiotics MeSH Descriptor Data 2018, Interleukin-17 MeSH Descriptor Data 2018
- Trial name
- NASHPro (NCT03511365)
- Testing
- Probiotic Formulation VSL#3
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Northwell Health
NAFLD
The Role of Microbiome Reprogramming on Liver Fat Accumulation
The purpose of this study is to investigate whether reprogramming the microbiome via soluble fiber supplementation will decrease liver fat in obese individuals.
- Trial name
- MILE (NCT03914495)
- Testing
- Inulin
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Non-alcoholic Fatty Liver Disease
The Efficacy and Safety of Ornithine Aspartic Acid Granules in NAFLD Against Silymarin Capsules
This is a multicenter, randomized, double-blind, double-dummy, and positive control clinic trial which explores the efficacy and safety of ornithine aspartate granules in the treatment of non-alcoholic fatty liver disease against…
- Trial name
- NCT05042245
- Testing
- Ornithine aspartate granule, Silymarin capsule, Silymarin capsule simulant
- Where
- China
- Volunteers
- 237 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Diabetes Mellitus, Type II, Fatty Liver
Study of INT-747 in Patients With Diabetes and Presumed NAFLD
The primary objectives of this study are to assess, in patients with Type 2 diabetes mellitus (DM) and presumed nonalcoholic fatty liver disease (NAFLD), the following: The safety and tolerability of multiple doses of INT 747…
- Trial name
- NCT00501592
- Testing
- INT-747
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- Intercept Pharmaceuticals
Women's Health, Hybrid Training
Hybrid Training and Middle Age
Modern living and physical inactivity results in many ailments, including obesity, non-alcoholic fatty liver disease (NAFLD), and inflammatory issues.
- Conditions
- Women's Health, Hybrid Training, Middle Aged, Non-alcoholic Fatty Liver Disease
- Trial name
- NCT05231564
- Testing
- hybrid training
- Where
- Iran
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Sistan and Baluchestan
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Steato-Hepatitis (NASH)
How Abnormal Function of Fat Tissue in Type 1 Diabetes Contributes to Fat in the Liver
Steatotic liver disease associated with metabolic dysfunction (MASLD) is a disease caused by excess fat storage in the liver. Excessive fat delivery to the liver and MASLD typically occurs in people with abdominal obesity and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Steato-Hepatitis (NASH), Type 1 Diabetes Mellitus
- Trial name
- AGL14 (NCT07133854)
- Testing
- Imaging PET/MRI, Stable isotope infusions, meal test
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Université de Sherbrooke
NASH - Nonalcoholic Steatohepatitis
The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology
The HepQuant SHUNT test, which is provided as a HepQuant SHUNT Liver Diagnostic Kit, is a minimally-invasive test of liver function and physiology which has been designated by the FDA as an investigational drug/device combination…
- Trial name
- NCT03294941
- Testing
- HepQuant SHUNT Liver Diagnostic Kit
- Where
- 8 sites in United States
- Volunteers
- 17 people
- Sponsor
- HepQuant, LLC
Non-alcoholic Fatty Liver Disease
Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
Studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis.
- Trial name
- NCT02875392
- Testing
- 275mg Oligo Fucoidan + 275mg HS Fucoxanthin
- Where
- Taiwan
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University WanFang Hospital
Non-alcoholic Fatty Liver Disease (NAFLD)
The Ameliorative Effect of C-Kit (+) Hepatic Endothelial Cells With Mertk Deficiency on Nonalcoholic Steatohepatitis
The prevalence of non-alcoholic fatty liver disease (NAFLD) has been steadily increasing, with 10-20% of affected individuals progressing to non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT06913699
- Testing
- Ultrasonund-guided percutaneous liver biopsy
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shanghai East Hospital
Non-Alcoholic Fatty Liver Disease
Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT
This study will be conducted upon the patients with fatty liver disease. Patients who will be diagnosed as a case of fatty liver disease by ultrasound with raised liver enzyme (ALT) will be primarily selected for the study.
- Trial name
- NAFLD (NCT03836937)
- Testing
- Obeticholic acid
- Where
- Bangladesh
- Volunteers
- 70 people
- Sponsor
- Sir Salimullah Medical College Mitford Hospital
Epilepsy, Cardiovascular Disease
Impact of Ketogenic Diet on Lipoproteins in Refractory Epilepsy
The ketogenic diet is a non-pharmacological treatment prescribed especially for children and indicated in most specialized centers for patients with refractory epilepsy.
- Conditions
- Epilepsy, Cardiovascular Disease, Non-alcoholic Fatty Liver Disease, Quality of Life
- Trial name
- Ketonutri (NCT02644239)
- Testing
- ketogenic diet
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo
Nonalcoholic Steatohepatitis (NASH)
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH
This is a phase 2, randomized, double-blind, placebo controlled study in adults with biopsy confirmed NASH. The study is aimed at evaluating efficacy and tolerability of ASC41 in adults with NASH.
- Trial name
- NCT05118360
- Testing
- ASC41 2 mg, ASC41 4 mg
- Sponsor
- Gannex Pharma Co., Ltd.
Non-Alcoholic Fatty Liver Disease, Obesity
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
Nonalcoholic fatty liver disease (NAFLD) is common in individuals with obesity and is a significant threat to public health, because it can lead to impaired liver function and liver failure.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal, Liver Fat
- Trial name
- NCT03375788
- Testing
- Tesamorelin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Massachusetts General Hospital
Non-Alcoholic Fatty Liver Disease
Dynamic Changes and Risk Factors of Fibrosis and Steatosis Progression in Nonalcoholic Fatty Liver Disease
It is an observational study of non alcoholic fatty liver disease (NAFLD) patients with a calculated sample size of 500. Liver biopsy proved NAFLD patients will be recruited in this study for 10 years follow-up.
- Trial name
- NCT03635541
- Testing
- observational group of NAFLD
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Beijing Friendship Hospital
Nonalcoholic Fatty Liver, Weight Loss
Study on GS300 on NAFLD
To determine the efficacy of GS300 when administered for 24 weeks in patients with Nonalcoholic Fatty Liver Disease (NAFLD).
- Trial name
- REVERT (NCT04887766)
- Testing
- GS300
- Volunteers
- 250 people
- Sponsor
- Gelesis, Inc.
Nonalcoholic Steatohepatitis
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).
- Trial name
- SYNERGY-NASH (NCT04166773)
- Testing
- Tirzepatide
- Where
- 112 sites in United States, Belgium and 8 more
- Volunteers
- 190 people
- Sponsor
- Eli Lilly and Company
Non-Alcoholic Fatty Liver Disease, Total Pancreatectomy
Hepatic Metabolic Changes in Response to Glucagon Infusion
The objective of the study is to investigate how exogenously administered glucagon affects hepatic lipid, glucose and protein metabolism as well as appetite, food intake and resting energy expenditure.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Total Pancreatectomy, Diabetes Mellitus
- Trial name
- NCT03526445
- Testing
- Glucagon, Saline
- Where
- Denmark
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Steno Diabetes Center Copenhagen
Non-alcoholic Fatty Liver Disease (NAFLD)
Combined Intensive and Conventional Exercise on Nonalcoholic Fatty Liver Disease (NAFLD)
The prevalence of NAFLD is 50-70% in obese people. A decrease of calorie intake and increase of physical activity are recommended as an effective approach for the prevention and treatment of NAFLD.
- Trial name
- NCT01418027
- Testing
- Intensive exercise, Conventional exercise
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Nonalcoholic Steatohepatitis
Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
The primary objectives of this study are: To assess the safety and tolerability of selonsertib (SEL), firsocostat (FIR) and cilofexor (CILO), administered alone or in combination, in participants with bridging fibrosis or…
- Trial name
- ATLAS (NCT03449446)
- Testing
- SEL, FIR, CILO
- Where
- 101 sites in United States, Australia and 4 more
- Volunteers
- 395 people
- Sponsor
- Gilead Sciences
Non-Alcoholic Fatty Liver Disease
Evaluation of Lipid Profile in Different Grades of Non-alcoholic Fatty Liver Disease Diagnosed by Ultrasound
Liver cells play a major role in the regulation of lipid metabolism. They are the principal location for lipoprotein and cholesterol synthesis.
- Trial name
- NCT05486429
- Testing
- Abdominal ultrasound and lipid profile
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University